(Adjusted Capital Asset Pricing Model), 563 Acceptable Risk, 96
Index Absorption, 40 Assets, 554–555 ACAPM (adjusted capital asset pricing model), fixed, 577–578 563 intangible, 556–557 Acceptable risk, 96 liquidation value of, 64 Accountants, 312–315 replacement, 577 Accounting earnings, 537–538 specialized, 236 Accounting principles, 587–590 Assignment for benefit of creditors (ABC), 339– Accounts receivable: 343, 348 collection of past due, 81 Attorneys. See Counsel discounting, 74–75 Audits, 221 Accounts receivable (A/R) financing, 101–102, Avanir Pharmaceuticals, 365–366 332–335, 356, 357 Accredited investor, 84 Balance sheet, 53, 221, 553–561 Accrual accounting system, 538 analysis of, 17 Accrual revenues, 538 liquidation, 64 Acquisition, reverse, 194–195 Band of Angels, 359 Acquisition company, 194 Bank debt, 162 Acquisitions, 37–41, 252, 542 Bankers, 306–312 case study, 344–347, 378–379, 385–387, Bankruptcy, 258, 336, 341, 348, 386 389–392 Banks. See Commercial banks; Merchant banks reasons for, 37 Barnette, Meg, 374 Adjusted book value, 28 Bartering, 75 Adjusted capital asset pricing model (ACAPM), Basic 7(a) loans, 176–181 563 BATNA (best alternative to a negotiated Advance rates, 105, 107, 109 acquisition), 325 Affirmative covenants, 223, 224, 278, 290 Becker, Michael, 382 Agency costs, 47 Beneficial owners, 19 AIM Market, 195–196 Benefits, employee, 559–560 Alignment, 7–36 Biotechnology industry, 123, 196, 200–201 Allocated costs, 539 Blank check preferred stock, 283 Amortization, 537 Board of directors, 145–146, 276, 303–306 Anderson, Jim, 198–199 managing, 147–151 Angel investments, 83–95 Book, the, 321 case study, 359–361 Bootstrapping, 72–82, 160 groups of, 87–89 Borrowers: latest developments in, 93 financial statements, 220–222 source directory by minimum funding, 400 operations, 222–223 vs.
[Show full text]